Neonatal Catheter Lock for Infection Prevention
NCT07585188 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 576
Last updated 2026-05-13
Summary
For newborns admitted to Neonatal Intensive Care Units (NICUs), one of the main risk factors for late-onset sepsis is the presence of a central venous catheter (CVC), which is often essential for the administration of medications and parenteral nutrition in this patient population. From a nosological perspective, sepsis associated with the presence of a venous catheter is defined by two acronyms: CRBSI (Catheter-Related Bloodstream Infection - a microbiological definition) and CLABSI (Central Line-Associated Bloodstream Infection - an epidemiological definition).
Among preventive strategies for CRBSI/CLABSI, antibiotic or antimicrobial catheter lock solutions - instilled in a volume equivalent to the catheter dead space and retained within the lumen until the next use - have demonstrated favorable efficacy in reducing infection risk.
Taurolidine 2% is considered a preferred agent due to its broad-spectrum antibacterial and antifungal activity and its lack of association with the development of antimicrobial resistance.
However, its prophylactic use in neonates remains largely investigational, with current evidence limited to small, retrospective observational studies involving catheters ≥3 Fr (e.g., femoral inserted central catheters - FICCs, centrally inserted central catheters - CICCs, and umbilical venous catheters).
In NICUs, epicutaneo-caval catheters (ECCs) are the most commonly used central venous access devices and represent a major source of catheter-related infections. Despite this, the use of antimicrobial lock prophylaxis in ECCs has been limited by concerns regarding catheter occlusion, given their smaller diameter (≤2 Fr). Nevertheless, available evidence indicates that short-duration locks, when combined with meticulous infusion line management, can be safely implemented without increasing the risk of catheter occlusion.
The aim of the study is to evaluate the efficacy of 2% taurolidine lock in the prevention of CLABSI/CRBSI in neonates with CVC (ECC, FICC, or CICC).
Conditions
- CLABSI - Central Line Associated Bloodstream Infection
- CRBSI - Catheter Related Bloodstream Infection
- Neonatal Sepsis, Late-Onset
Interventions
- DEVICE
-
Taurolidine 2% lock
Lock with a 2% taurolidine solution for a duration of 30 minutes every 48 hours, from CVC insertion until its removal, performed in newborns with epicutaneo-caval catheters (ECCs), femoral inserted central catheters (FICCs), or centrally inserted central catheters (CICCs).
- OTHER
-
Normal saline lock
Lock with normal saline for a duration of 30 minutes every 48 hours, from CVC insertion until its removal, performed in newborns with epicutaneo-caval catheters (ECCs), femoral inserted central catheters (FICCs), or centrally inserted central catheters (CICCs).
Sponsors & Collaborators
-
University of Turin, Italy
lead OTHER
Principal Investigators
-
Elena Maggiora, MD · University of Turin, Italy
-
Francesco Cresi, MD PhD · University of Turin, Italy
-
Giulia Maiocco, MD · University of Turin, Italy
-
Alessandra Coscia, MD PhD · University of Turin, Italy
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Day
- Max Age
- 120 Days
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-10-31
- Primary Completion
- 2029-10-31
- Completion
- 2029-10-31
Countries
- Italy
Study Locations
More Related Trials
-
Effect of Taurolidin on Prevention of Bloodstream Infection
NCT00545831 ·Status: TERMINATED ·Phase: NA
-
Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency
NCT01101087 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.
NCT01948245 ·Status: UNKNOWN ·Phase: PHASE4
-
Taurolidine in Haemodialysis Catheter Related Bacteraemia
NCT01243710 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction
NCT02789501 ·Status: COMPLETED ·Phase: PHASE4
-
ATAPAC Study (TauroLock Activity in Adult Cancer Patients)
NCT02279121 ·Status: COMPLETED ·Phase: NA
-
Ethanol-lock Therapy for the Prevention of Non-tunneled Catheter-related Infection in Pediatric Patients
NCT03253887 ·Status: COMPLETED ·Phase: PHASE3
-
Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients
NCT04559334 ·Status: SUSPENDED ·Phase: NA
-
Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a "LOOSEN" Pilot Study
NCT05729321 ·Status: UNKNOWN
-
Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections
NCT06660641 ·Status: COMPLETED ·Phase: NA
-
Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
NCT07259421 ·Status: NOT_YET_RECRUITING
-
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
NCT06714864 ·Status: RECRUITING ·Phase: PHASE4
-
Study of the Use of Coated Venous Catheters in the Critically Ill Child
NCT00202813 ·Status: COMPLETED ·Phase: PHASE4
-
Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?
NCT00749619 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%
NCT01826526 ·Status: COMPLETED ·Phase: NA
-
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426 ·Status: RECRUITING ·Phase: PHASE3
-
Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
NCT01472965 ·Status: COMPLETED ·Phase: PHASE3
-
Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)
NCT01539343 ·Status: COMPLETED ·Phase: PHASE2
-
Neutrolin Versus Heparin for Locking Hemodialysis Catheters
NCT03425448 ·Status: UNKNOWN ·Phase: NA
-
Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase
NCT02036255 ·Status: COMPLETED ·Phase: PHASE3
-
Pediatric Ethanol Lock Therapy Study.
NCT00948441 ·Status: COMPLETED ·Phase: NA
-
CLABSI Prevention With Tissue Adhesive
NCT05721677 ·Status: RECRUITING ·Phase: NA
-
Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
NCT06707480 ·Status: AVAILABLE
-
Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition
NCT02255318 ·Status: UNKNOWN ·Phase: NA
-
Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection
NCT05576194 ·Status: COMPLETED